By Memorandum Opinion entered by The Honorable Gregory M. Sleet in Recro Gainesville LLC v. Actavis Laboratories FL, Inc., Civil Action No. 14-1118-GMS (D.Del. February 24, 2017)(consolidated), the Court, following a three-day bench trial and having considered the entire record in the case and the applicable law, concluded that Actavis’ proposed ANDA products infringe all of the asserted claims of U.S. Patent No. 9,132,096 (“the ‘096 patent”) and U.S. Patent No. 6,902,742 (“the ‘742 patent”). As a result, the Court ordered that, pursuant to 35 U.S.C. §271(e)(4)(A), the effective date of any FDA approval of Actavis’ proposed ANDA products shall not be earlier than the later expiration date of the ‘096 and ‘742 patents. Id. at *28. The Court, pursuant to 35 U.S.C. §271(e)(4)(B), also enjoined Actavis, its officers, agents, attorneys, and employees, and those acting in privity or concert with any of them, from engaging in the commercial manufacture, use, offer to sell, or sale within the United States, or importation into the United States of Actavis’ ANDA products prior to the expiration of the ‘096 and’742 patents. Id.

A copy of the Memorandum Opinion is attached.